These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20829612)

  • 1. Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells.
    Hofland LJ; Lamberts SW; Feelders RA
    Neuroendocrinology; 2010; 92 Suppl 1():11-6. PubMed ID: 20829612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.
    Boschetti M; Gatto F; Arvigo M; Esposito D; Rebora A; Talco M; Albertelli M; Nazzari E; Goglia U; Minuto F; Ferone D
    Neuroendocrinology; 2010; 92 Suppl 1():17-22. PubMed ID: 20829613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary tumours: the sst/D2 receptors as molecular targets.
    Hofland LJ; Feelders RA; de Herder WW; Lamberts SW
    Mol Cell Endocrinol; 2010 Sep; 326(1-2):89-98. PubMed ID: 20438803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of somatostatin analogs in Cushing's disease.
    van der Hoek J; Lamberts SW; Hofland LJ
    Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
    de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
    J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
    Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease.
    Giordano R; Picu A; Bonelli L; Broglio F; Prodam F; Grottoli S; Muccioli G; Ghigo E; Arvat E
    Eur J Endocrinol; 2007 Oct; 157(4):393-8. PubMed ID: 17893252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptors in pituitary function, diagnosis and therapy.
    Hofland LJ; Lamberts SW
    Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.
    Mannelli M; Cantini G; Poli G; Mangoni M; Nesi G; Canu L; Rapizzi E; Borgogni E; Ercolino T; Piccini V; Luconi M
    Neuroendocrinology; 2010; 92 Suppl 1():23-7. PubMed ID: 20829614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease.
    Suárez-Llanos JP; Fernández-Fernández E; Checa MR; Jara-Albarrán A
    Neuro Endocrinol Lett; 2007 Oct; 28(5):549-53. PubMed ID: 17984930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.